Journal
HAEMATOLOGICA
Volume 106, Issue 9, Pages 2325-2333Publisher
FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.2020.254623
Keywords
-
Categories
Funding
- Subdireccion General de Investigacion Sanitaria (Instituto de Salud Carlos III, Spain) [PI13/02387, PI16/01530]
- CRIS against Cancer foundation [2014/0120]
- Spanish Ministry of Economy and Competitiveness [FPDI-2013-16409]
Ask authors/readers for more resources
In cases of treatment failure in acute myeloid leukemia (AML), mutational profiling can help differentiate primary refractoriness from relapse, providing insights for treatment guidance and prognostic risk assessment. Additionally, molecular follow-up using a custom NGS myeloid panel can aid in monitoring treatment response, identifying minimal residual disease markers, guiding post-remission strategies, and selecting new drugs for leukemia relapse.
In cases of treatment failure in acute myeloid leukemia (AML), the utility of mutational profiling in primary refractoriness and relapse is not established. We undertook a perspective study using next-generation sequencing (NGS) of clinical follow-up samples (n=91) from 23 patients with AML with therapeutic failure to cytarabine plus idarubicin or fludarabine. Cases of primary refractoriness to treatment were associated with a lower number of DNA variants at diagnosis than cases of relapse (median 1.67 and 3.21, respectively, P=0.029). The most frequently affected pathways in patients with primary refractoriness were signaling, transcription and tumor suppression, whereas methylation and splicing pathways were mainly implicated in relapsed patients. New therapeutic targets, either by an approved drug or within clinical trials, were not identified in any of the cases of refractoriness (zero of ten); however, eight potential new targets were found in five relapsed patients (five of 13, P=0.027): one IDH2, three SF3B1, two KRAS, one KIT and one JAK2. Sixty-five percent of all variants detected at diagnosis were not detected at complete response. Specifically, 100% of variants in EZH2, RUNX1, VHL, FLT3, ETV6, U2AF1, PHF6 and SF3B1 disappeared at complete response, indicating their potential use as markers to evaluate minimal residual disease for follow-up of AML. Molecular follow-up using a custom NGS myeloid panel of 32 genes in the post-treatment evaluation of AML can help in the stratification of prognostic risk, the selection of minimal residual disease markers to monitor the response to treatment and guide post-remission strategies targeting AML, and the selection of new drugs for leukemia relapse.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available